Androgens and hair loss

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 3, 2009, Pages 246-253

  Alsantali, Adel ^a   Shapiro, Jerry ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgenetic alopecia; Androgens; Finasteride; Male pattern hair loss; Minoxidil

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DUTASTERIDE; FINASTERIDE; MINOXIDIL; AZASTEROID; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

CHROMOSOME 20; CHROMOSOME 3; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; DERMATITIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; EJACULATION; ETHNIC DIFFERENCE; GENE LOCUS; GENETIC ANALYSIS; GENOME ANALYSIS; GYNECOMASTIA; HAIR TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMPOTENCE; IN VITRO STUDY; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIBIDO; LOW LEVEL LASER THERAPY; MALE TYPE ALOPECIA; PATHOGENESIS; PREVALENCE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PRURITUS; PSYCHOLOGICAL ASPECT; RECEPTOR GENE; REVIEW; SCALE UP; SIDE EFFECT; SPERMATOZOON COUNT; ALOPECIA; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC PREDISPOSITION; HAIR; INTRADERMAL DRUG ADMINISTRATION; MALE; METABOLISM; RISK FACTOR; TRANSPLANTATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ALOPECIA; ANDROGENS; ANIMALS; AZASTEROIDS; ENZYME INHIBITORS; FINASTERIDE; GENETIC PREDISPOSITION TO DISEASE; HAIR; HUMANS; MALE; MINOXIDIL; RISK FACTORS; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 66349100828     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832b100a     Document Type: Review

References (94)

1. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3:1873-1876. (Pubitemid 24310487)
2. Garton RA, McMichael AJ, Sugarman J, et al. Association of a polymorphismin the ornithine decarboxylase gene with male androgenetic alopecia. J Am Acad Dermatol 2005; 52:535-536.
3. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116:452-455. (Pubitemid 32202911)
4. Hillmer AM, Hanneken S, Ritzmann S, et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005; 77:140-148. (Pubitemid 40848045)
5. Ellis JA, Scurrah KJ, Cobb JE, et al. Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. Hum Genet 2007; 121:451-457.
6. Prodi DA, Pirastu N, Maninchedda G, et al. EDA2R is associated with androgenetic alopecia. J Invest Dermatol 2008; 128:2268-2270.
7. Hillmer AM, Brockschmidt FF, Hanneken S, et al. Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat Genet 2008; 40:1279-1281. This study describes a new susceptibility gene associated with AGA, which could explain the inheritance of AGA from the father's side.
8. Richards JB, Yuan X, Geller F, et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008; 40:1282-1284.
9. Hillmer AM, Flaquer A, Hanneken S, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet 2008; 82:737-743.
10. Zouboulis CC, Degitz K. Androgen action on human skin: from basic research to clinical significance. Exp Dermatol 2004; 13:5-10. (Pubitemid 39654434)
11. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001; 116:793-800. (Pubitemid 32467662)
12. Courchay G, Boyera N, Bernard BA, et al. Messenger RNA expression of steroidogenesis enzyme subtypes in the human pilosebaceous unit. Skin Pharmacol 1996; 9:169-176. (Pubitemid 26149686)
13. Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990; 126:1165-1172.
14. Bayne EK, Flanagan J, Einstein M, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol 1999; 141:481-491. (Pubitemid 29448409)
15. Penning TM, Pawlowski JE, Schlegel BP, et al. Mammalian 3 alphahydroxysteroid dehydrogenases. Steroids 1996; 61:508-523.
16. Sawaya ME, Price VH. Different levels of 5 alpha-reductase Type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109:296-300.
17. Sawaya ME, Hordinsky MK. Advances in alopecia areata and androgenetic alopecia. Adv Dermatol 1992; 7:211-226.
18. Verrijdt G, Haelens A, Claessens F. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 2003; 78:175-185. (Pubitemid 36335810)
19. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from nonbalding scalp. J Endocrinol 1998; 156:59-65.
20. Sawaya ME, Honig LS, Hsia SL. Increased androgen binding capacity in sebaceous glands in scalp of male-pattern baldness. J Invest Dermatol 1989; 92:91-95.
21. Lee P, Zhu CC, Sadick NS, et al. Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia. J Cutan Pathol 2005; 32:567-571. (Pubitemid 41224426)
22. Inui S, Fukuzato Y, Nakajima T, et al. Androgen receptor co-activator Hic-5/ARA55 as a molecular regulator of androgen sensitivity in dermal papilla cells of human hair follicles. J Invest Dermatol 2007; 127:2302-2306. (Pubitemid 47619758)
23. Inui S, Fukuzato Y, Nakajima T, et al. Androgen-inducible TGF-beta1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understand paradoxical effects of androgen on human hair growth. FASEB J 2002; 16:1967-1969.
24. Kwack MH, Sung YK, Chung EJ, et al. Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J Invest Dermatol 2008; 128:262-269.
25. Courtois M, Loussouarn G, Hourseau C, et al. Hair cycle and alopecia. Skin Pharmacol 1994; 7:84-89.
26. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002; 4:1-11.
27. Smith MA, Wells RS. Male-type alopecia, alopecia areata, and normal hair in women. Arch Dermatol 1964; 89:155-158.
28. Hamilton J. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci 1951; 53:708-728.
29. Birch MP, Messenger AG. Genetic factors predispose to balding and nonbalding in men. Eur J Dermatol 2001; 11:309-314.
30. Chumlea WC, Rhodes T, Girman CJ, et al. Family history and risk of hair loss. Dermatology 2004; 209:33-39. (Pubitemid 39179103)
31. Setty LR. Hair patterns of scalp of white and Negro males. Am J Phys Anthropol 1970; 33:49-55.
32. Xu F, Sheng YY, Mu ZL, et al. Prevalence and types of androgenetic alopecia in Shanghai, China: a community-based study. Br J Dermatol 2008; 160:629-632.
33. Tang PH, Chia HP, Cheong LL, et al. A community study of male androgenetic alopecia in Bishan, Singapore. Singapore Med J 2000; 41:202-205.
34. Paik JK, Yoon JB, Sim WY, et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001; 145:95-99.
35. Pathomvanich D, Pongratananukul S, Thienthaworn P, et al. A random study of Asian male androgenetic alopecia in Bangkok, Thailand. Dermatol Surg 2002; 28:804-807. (Pubitemid 35014682)
36. Norwood O. Male pattern baldness: classification and incidence. South Med J 1975; 68:1359-1365.
37. Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am 2007; 36:379-398.
38. Lee WS, Ro BI, Hong SP, et al. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol 2007; 57:37-46.
39. Rebora A. Baldness and coronary artery disease: the dermatologic point of view of a controversial issue. Arch Dermatol 2001; 137:943-947. (Pubitemid 32641656)
40. Matilainen VA, Mäkinen PK, Keinänen-Kiukaanniemi SM. Early onset of androgenetic alopecia associated with early severe coronary heart disease: a population-based, case-control study. J Cardiovasc Risk 2001; 8:147-151.
41. Herrera CR, D'Agostino RB, Gerstman BB, et al. Baldness and coronary heart disease rates in men from the Framingham Study. Am J Epidemiol 1995; 142:828-833.
42. Lotufo PA, Chae CU, Ajani UA, et al. Male pattern baldness and coronary heart disease: the Physicians' Health Study. Arch Intern Med 2000; 160: 165-171. (Pubitemid 30054335)
43. Sasmaz S, Senol M, Ozcan A, et al. The risk of coronary heart disease in men with androgenetic alopecia. J Eur Acad Dermatol Venereol 1999; 12:123-125. (Pubitemid 29234445)
44. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial infarction in men. JAMA 1993; 269:998-1003. (Pubitemid 23066636)
45. Mansouri P, Mortazavi M, Eslami M, Mazinani M. Androgenetic alopecia and coronary artery disease in women. Dermatol Online J 2005; 11:2. (Pubitemid 43034778)
46. Shahar E, Heiss G, Rosamond WD, Szklo M. Baldness and myocardial infarction in men: the atherosclerosis risk in communities study. Am J Epidemiol 2008; 167:676-683.
47. Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. Early androgenetic alopecia as a marker of insulin resistance. Lancet 2000; 356:1165-1166. (Pubitemid 30769388)
48. Hirsso P, Rajala U, Hiltunen L, et al. Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. Dermatology 2007; 214:125-129. (Pubitemid 46377236)
49. Hirsso P, Laakso M, Matilainen V, et al. Association of insulin resistance linked diseases and hair loss in elderly men. Finnish population-based study. Cent Eur J Public Health 2006; 14:78-81. (Pubitemid 44014533)
50. Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol 2007; 17:220-222.
51. Demark-Wahnefried W, Lesko SM, Conaway MR, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl 1997; 18:495-500. (Pubitemid 27454306)
52. Hsieh CC, Thanos A, Mitropoulos D, et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999; 80:699-703. (Pubitemid 29066281)
53. Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2000; 9:523-527. (Pubitemid 30313897)
54. Giles GG, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev 2002; 11:549-553. (Pubitemid 34615162)
55. Oh BR, Kim SJ, Moon JD, et al. Association of benign prostatic hyperplasia with male pattern baldness. Urology 1998; 51:744-748.
56. Budd D, Himmelberger D, Rhodes T, et al. The effects of hair loss in European men: a survey in four countries. Eur J Dermatol 2000; 10:122-127. (Pubitemid 30116425)
57. Cash T. The psychological effect's of androgenetic alopecia in men. J Am Acad Dermatol 1992; 26:926-931.
58. Alfonso M, Richter-Appelt H, Tosti A, et al. The psychosocial impact of hair loss among men: a multinational European study. Curr Med Res Opin 2005; 21:1829-1836. (Pubitemid 41667251)
59. Wells PA, Willmoth T, Russell RJ. Does fortune favour the bald? Psychological correlates of hair loss in males. Br J Psychol 1995; 86:337-344. (Pubitemid 126418058)
60. Lee HJ, Ha SJ, Kim D, et al. Perception of men with androgenetic alopecia by women and nonbalding men in Korea: how the nonbald regard the bald. Int J Dermatol 2002; 41:867-869. (Pubitemid 36075224)
61. Giorgi A, Weatherby RP, Murphy PW. Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study. J Sci Med Sport 1999; 2:341-355. (Pubitemid 30043851)
62. Tosti A, Whiting D, Iorizzo M, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol 2008; 59:64-67.
63. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol 2006; 55:799-806. (Pubitemid 44556832)
64. Whiting D. Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatol Ther 1998; 8:24-33. (Pubitemid 29074657)
65. Sperling LC, Winton GB. The transverse anatomy of androgenic alopecia. J Dermatol Surg Oncol 1990; 16:1127-1133.
66. Sperling L. An atlas of hair pathology with clinical correlations. New York, NY: The Parthenon Publishing Group; 2003.
67. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999; 41:550-554. (Pubitemid 29480402)
68. Bolduc C, Shapiro J. Management of androgenetic alopecia. Am J Clin Dermatol 2000; 1:151-158.
69. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39:578-589.
70. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1mg daily): three-and 4-year results. J Am Acad Dermatol 2006; 55:71-74. (Pubitemid 43884854)
71. Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000; 143:804-810. (Pubitemid 30807693)
72. Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999; 162:1295-1300. (Pubitemid 29428566)
73. Pannek J, Marks LS, Pearson JD, et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998; 159:449-453. (Pubitemid 28049254)
74. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8:21-25.
75. Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation. Pharm Dev Technol 2007; 12:591-601.
76. Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalp: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol 1984; 82:515-517. (Pubitemid 14101289)
77. Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol 1987; 117:668-669.
78. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138:407-411. (Pubitemid 28145505)
79. Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stumptailed macaque. J Am Acad Dermatol 1987; 16:657-658. (Pubitemid 17031771)
80. Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol 1990; 17:276-281. (Pubitemid 20321655)
81. Buhl AE, Waldon DJ, Conrad SJ, et al. Potassium channel conductance: a mechanism affecting hair growth in vitro and in vivo. J Invest Dermatol 1992; 98:315-319.
82. Buhl AE, Conrad SJ, Waldon DJ, Brunden MN. Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 1993; 101:148S-152S.
83. Uno H, Mori O, Cappas A, et al. The effect of topical minoxidil on sequential histological changes in alopecia totalis and universalis. J Invest Dermatol 1986; 86:512.
84. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47:377-385.
85. Ferry JJ, Shepard JH, Szpunar GJ. Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution. J Pharm Sci 1990; 79:483-486.
86. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57:767-774. (Pubitemid 47553065)
87. Olsen E, Weiner MS. Topical minoxidil in male pattern hair loss: effects of discontinuation of treatment. J Am Acad Dermatol 1987; 17:97-101. (Pubitemid 17087203)
88. Alert F. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209:117-125.
89. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002; 29:489-498. (Pubitemid 34988248)
90. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alphareductase inhibition in the treatment of male pattern hair loss: results of a randomised placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55:1014-1023.
91. Stough DB, Haber RS. Procedures in cosmetic surgery: hair transplantation. Philadelphia, PA: Elsevier Saunders; 2006.
92. Rousso DE, Presti PM. Follicular unit transplantation. Facial Plast Surg 2008; 24:381-388. This review article describes up-to-date techniques of follicular unit transplantation.
93. Bernstein RM, Rassman WR. Follicular Unit Transplantation: 2005. Dermatol Clin 2005; 23:393-414.
94. Harris J. Follicular unit extraction. Facial Plast Surg 2008; 24:404-413. This article describes the instrumentation and surgical methodology of follicular unit extraction.